Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.45 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.45 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11965677 | 0.92 | MAPK14 (0.54) | MAPK14CYP3A4CYP2C9MAPK11HPGD | |
| SCHEMBL11965672 | 0.90 | MAPK14 (0.53) | MAPK14CYP3A4CYP2C9MAPK11HPGD | |
| SCHEMBL1382659 | 0.88 | MAPK14 (0.50) | MAPK14CYP3A4CYP2C9MAPK11HPGD | |
| SCHEMBL11982541 | 0.84 | MAPK14 (0.53) | MAPK14CYP3A4CYP2C9MAPK11 | |
| SCHEMBL11982584 | 0.82 | MAPK14 (0.51) | MAPK14CYP3A4CYP2C9MAPK11 | |
| SCHEMBL1417107 | 0.82 | MAPK14 (0.51) | MAPK14CYP3A4CYP2C9MAPK11 | |
| SCHEMBL1384078 | 0.82 | MAPK14 (0.51) | MAPK14CYP3A4CYP2C9MAPK11 | |
| SCHEMBL1384415 | 0.81 | MAPK14 (0.50) | MAPK14CYP3A4CYP2C9MAPK11 | |
| SCHEMBL1382689 | 0.81 | MAPK14 (0.49) | MAPK14CYP3A4CYP2C9MAPK11HPGD | |
| SCHEMBL1383749 | 0.81 | MAPK14 (0.49) | MAPK14CYP3A4CYP2C9MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580838-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8410160-B2 | 5-membered heterocycle-based P38 kinase inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120264801-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-8242117-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20110071152-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885CYP3A4 2339/4885CYP2C9 2939/4885 |
| US-20120264801-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885CYP3A4 2339/4885CYP2C9 2939/4885 |
| US-20110071152-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885CYP3A4 2146/4885CYP2C9 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.